Results demonstrate significant reduction in blood glucose, blood
pressure, HbA1c and waist circumference
EDMONTON, March 21 /CNW/ - Good news for some of the 120,000 Albertans
who have diabetes(1), a condition that, if left untreated, can lead to heart
disease, kidney disease or nerve damage. A clinical trial conducted in China
demonstrated that a structured intervention program that includes the
nutritional supplement Glucerna along with blood glucose monitoring, diabetes
education and dietary and nutrition modification significantly reduced key
metabolic markers - glycosylated hemoglobin (HbA1c), fasting plasma glucose,
systolic and diastolic blood pressure, weight and waist circumference - in
overweight patients with type 2 diabetes, compared to baseline. These
findings, published in the American Diabetes Association 66th Scientific
Sessions Abstract Book, demonstrate the value of such a structured
intervention program in helping overweight people with type 2 diabetes(2).
The randomized, controlled clinical trial was conducted on 150 patients
in Shanghai, China over six months. For 100 patients, blood glucose
monitoring, caloric control using Glucerna once daily as a meal replacement,
diabetes education and dietary modification were added to the usual diabetes
care given to the 50 patients in the control group.
After six months, patients in the intervention group had reduced their
weight from an average of 75.7 kg to 72.8 kg (p(less than)0.0001), their
fasting glucose from 8.62 mmol/L to 7.39 mmol/L (p(less than)0.0001) and their
HbA1c levels from 7.1 to 6.3 (p(less than)0.001). Systolic blood pressure was
reduced from an average of 131.2 to 123.7 (p(less than)0.0001) and diastolic
blood pressure from 87.0 to 83.8 (p(less than)0.0001). Patients in the control
group reduced their weight from an average of 75.6 kg to 73.8 kg (p(less
than)0.05), but did not see significant reductions in any other key metabolic
"Nutrition is an essential component of diabetes management," said Farhad
Zangeneh, MD, FACP, FACE, Assistant Clinical Professor of Medicine at the
George Washington University School of Medicine in Washington, DC and Medical
Director of the Endocrine, Diabetes and Osteoporosis Clinic in Sterling,
Virginia, USA. "The study results are very encouraging and show that there are
tools to help patients manage this disease. Optimal diabetes management
improves metabolic outcomes, reduces complications and improves quality of
Glucerna is the first nutritional supplement to show an effect on blood
pressure, blood glucose and waist circumference, important markers for overall
health, when integrated into a diabetes management program that also includes
blood glucose monitoring, diabetes education and dietary modification.
Glucerna contains a specialized, slowly released carbohydrate system
formulated to provide lower peak glucose levels than a standard medical
nutritional liquid or snack bar(3,4).
Evidence-based research strongly suggests that medical nutritional
management can help to achieve and maintain better metabolic control in
patients with diabetes(5) and previous research on Glucerna in patients with
type 2 diabetes showed that it provides more consistent blood glucose levels
compared to a standard medical nutritional liquid or snack bar(3,4).
Patients in the study were between 18 and 70 years old, had a body mass
index (BMI) greater than 23 kg/m(2), had been diagnosed with type 2 diabetes
and were not currently participating in any other disease management or
Patients in the intervention group were asked to monitor their blood
glucose four to six times a week (immediately before and one-to-two hours
after breakfast, lunch and dinner, respectively) and received specialized
nutrition counseling and diabetes education. All study participants were asked
to maintain their current level of physical activity.
Patients were evaluated at baseline, one week after baseline
(randomization occurred at this time), following one month, three months, and
six months of participation in the study. At the one-, three- and six-month
visits, patients were evaluated for weight, height, waist circumference and
The withdrawal rate for all subjects in the study was less than
The study was conducted by the Nutritional Sciences department of the
Chinese Academy of Sciences.
Glucerna products are pleasant-tasting oral nutritional shakes or snack
bars designed to provide complete balanced nutrition for patients with
diabetes. Glucerna contains a slowly digested carbohydrate system and a
modified fat-blend high in monounsaturated fatty acids that conform to
macronutrient guidelines (Canadian Diabetes Association and the European
Association for the Study of Diabetes) for nutrition of people with diabetes
mellitus (CDA 2002; EASD 2002). Glucerna has been tested in patients with type
2 diabetes and has been shown to provide more consistent blood glucose levels
compared to standard medical nutritional liquid or snack bar(2,3).
About Abbott Nutrition
Abbott Nutrition develops and markets a wide range of science-based
infant formulas, medical nutritionals, nutrition and energy bars, and related
products to support the growth, health and wellness of people of all ages.
Abbott Nutrition's internationally recognized brands include the Similac(R)
brand of infant formulas; the Gain(R) brand of growing-up milks for older
babies and toddlers; the PediaSure(R) brand of nutritionals and snacks for
children; and the Ensure(R) brand of adult nutritionals.
Additionally, Abbott Nutrition is a leader in medical foods clinically
shown to address the distinct dietary needs of people with serious health
conditions or special nutrient requirements, such as the Glucerna(R) brand of
nutrition shakes and bars for people with diabetes. Abbott Nutrition also
offers specialized nutrition products to meet the unique needs of competitive
About Abbott Canada
Abbott Canada, which is headquartered in Saint-Laurent, Quebec, employs
approximately 2,000 people and ranks as one of the 50 Best Employers in
Canada. In addition, Brockville, Ontario, is home to one of Abbott Nutrition's
11 manufacturing facilities throughout the world.
Abbott is a global, broad-based health care company devoted to the
discovery, development, manufacture and marketing of pharmaceuticals and
medical products, including nutritionals, devices and diagnostics. The company
employs 65,000 people and markets products in more than 130 countries.
(1) Diabète Québec, www.diabete.qc.ca.
(2) Sun J et al. Structured intervention on the management of overweight
patients with type 2 diabetes management in Shanghai China. 66th session
ADA, abstr, 2006.
(3) Fix BM, Lowe W, Cockram DB, Craig LD. Effect of a liquid nutritional
supplement containing a novel carbohydrate system on glucose tolerance on
subjects with type 2 diabetes. Ann Nutr Metab 2001;45(Suppl 1):277.
(4) Nicholson S, Garvey WT, Wallace P, et al. Prostprandial glucose and
insulin responses to dextrin-containing medical nutritional bars in
persons with type 2 diabetes mellitus. Diabetes 2001:50(Suppl 1):A366.
(5) Pastors JG, Warshaw H, Daly A. et al. The evidence for the
effectiveness of medical nutrition therapy in diabetes management.
Diabetes Care. 2002 Mar;25(3):608-13.
For further information:
For further information: Lyndsay Thorlacius, (403) 531-0331